Announcement today re US licencing agreement, page-13

22 July 2020• Zelira and Cardiovascular Solutions of Central Mississippi (CVSCM) enter into a binding agreement to develop and commercialize products that target symptoms associated with Peripheral Arterial Disease and Diabetic Neuropathies • Zelira will grant an exclusive license to CVSCM to manufacture, sell and otherwise commercialize Zelira’s proprietary formulations in the USA• Zelira will receive an upfront licensing fee and royalties on any commercialized products• CVSCM will be responsible for all costs relating to the production, marketing, distribution and sale of the products in the USA• This transaction expands and complements Zelira’s strategic interests in cardiovascular indications while maintaining focus on the global launch of its proprietary Zenivol™ and HOPE™ produ